Improvement of therapeutic index for brain tumors with daily image guidance
© Shields et al.; licensee BioMed Central Ltd. 2013
Received: 24 July 2013
Accepted: 26 November 2013
Published: 2 December 2013
Image-guidance maximizes the therapeutic index of brain irradiation by decreasing setup uncertainty. As dose-volume data emerge defining the tolerance of critical normal structures responsible for neuroendocrine function and neurocognition, minimizing clinical target volume (CTV) to planning target volume (PTV) expansion of targets near these structures potentially lessens long-term toxicity.
We reviewed the treatment records of 29 patients with brain tumors, with a total of 517 fractions analyzed. The CTV was uniformly expanded by 3 mm to create the PTV for all cases. We determined the effect of patient specific factors (prescribed medications, weight gain, tumor location) and image-guidance technique on setup uncertainty and plotted the mean +/- standard deviation for each factor. ANOVA was used to determine significance between these factors on setup uncertainty. We determined the impact of applying the initial three fraction variation as custom PTV-expansion on dose to normal structures.
The initial 3 mm margin encompassed 88% of all measured shifts from daily imaging for all fractions. There was no difference (p = n.s.) in average setup uncertainty between CBCT or kV imaging for all patients. Vertical, lateral, longitudinal, and 3D shifts were similar (p = n.s.) between days 1, 2, and 3 imaging and later fractions. Patients prescribed sedatives experienced increased setup uncertainty (p < 0.05), while weight gain, corticosteroid administration, and anti-seizure medication did not associate with increased setup uncertainty. Patients with targets near OAR with individualized margins led to decreased OAR dose. No reductions to targets occurred with individualized PTVs.
Daily imaging allows application of individualized CTV expansion to reduce dose to OAR responsible for neurocognition, learning, and neuroendocrine function below doses shown to correlate with long-term morbidity. The demonstrated reduction in dose to OAR in this study has implications for quality of life and provides the motivation to pursue custom PTV expansion.
The underlying goal of treating CNS malignancies is to maximize tumor eradication while preserving parenchymal brain function. Tilting the therapeutic index towards eradicating tumor cells while protecting normal tissue may be improved by reducing setup uncertainty. Image guided radiation therapy (IGRT) has the potential to improve accuracy through patient localization.
The term clinical target volume (CTV) is defined in the International Commission on Radiation Units and Measurements (ICRU) Reports as “a tissue volume that contains a gross tumor volume (GTV) which is the gross palpable or visible/demonstrable extent + and location of the malignant growth, and/or subclinical microscopic malignant disease, which has to be eliminated. This volume has to be treated adequately in order to reach the aim of therapy: cure or palliation” . Planning target volume (PTV) is defined as “a geometrical concept, and it is defined to select appropriate beam sizes and beam arrangements, taking into consideration the net effect of all the possible geometrical variations and inaccuracies in order to ensure that the prescribed dose is actually absorbed in the CTV” . The PTV is composed of two factors: (1) the internal margin (IM) which relies on temporal changes in position, volume, and shape of the CTV and the (2) setup margin (SM) which accounts for uncertainties in patient position and beam delivery that is inherent with fractionated irradiation [2–4]. If the margin between the CTV and PTV is too large, there is a higher likelihood of excessive radiation to normal tissue . Inversely, if the margin is too small, an undesirable outcome may occur due to inadequate radiation of the target tissue. The present study highlights patient features and technical interventions which may play a role in influencing the setup margin.
We tested the following hypotheses: 1) that the use of days 1, 2, and 3 cone-beam CT scan or orthogonal kV imaging predicted patient position during the treatment course, 2) non technology related patient factors, specifically a) prescribed medications b) weight gain, c) and tumor location predicted setup uncertainty, and 3) application of custom CTV to PTV expansion from the first three fractions reduces dose to organs at risk (OAR).
Under an IRB-approved protocol and in compliance with the Helsinki Declaration, we reviewed the treatment records of 29 patients with brain tumors immobilized with an aquaplast mask and standard base plate or an S-frame and aquaplast mask for simulation. The treatment planning CT with 1 mm neutral gantry axial slices was fused with a gadolinium-enhanced MRI with 3 mm zero tilt axial, coronal, and sagittal slices for target delineation. The CTV was uniformly expanded by 3 mm to create the PTV for all cases to minimize fusion errors. This approach is similar to a phantom study shown to have an accuracy of autofusion less than 0.5 mm . Anatomic verification of deep brain electrode placement based on CT/MRI fusion has been shown to have accuracy of a similar magnitude . OAR were contoured (temporal lobes, brainstem, bilateral hippocampus, cochlea, hypothalamus, and pituitary gland) and were used for inverse-planned static gantry IMRT. The equipment utilized was a Varian linear accelerator with orthogonal kilovoltage imagery.
All patients were treated with daily fractionated radiation with the dose dependent on tumor histology: 21 patients with high grade glioma received 60 Gy in 30 fractions; 4 patients with low grade glioma, 2 patients with meningioma, and 2 patients with pituitary adenoma received 50.4 Gy in 28 fractions. The number of beams and angles was chosen based on tumor location and proximity of OAR.
Patients found to have setup uncertainty less than 3 mm were planned with the measured setup uncertainty, with no change in optimization parameters. The setup uncertainty was dependent on the localization. A bony match as opposed to a soft tissue match was utilized since the base of the skull served as a surrogate for intracranial targets. We determined the effect of patient specific factors (prescribed medications, weight gain, and tumor location) and technical interventions on setup uncertainty, and plotted the mean +/- standard deviation for each factor. Student’s t-test was used to compare between groups.
Image Guidance Modality and Setup Uncertainty
We first determined the influence of Cone Beam Computed Tomography (CBCT) versus On Board Imaging (OBI) imaging on patient set up variability. For each of the 29 patients, shift data was recorded and analyzed for both techniques. There was no difference between techniques for shifts in the vertical (2+/-4 mm CBCT vs 2+/-2 mm OBI, p = 0.45), longitudinal (1.3+/-1.4 mm CBCT vs 1.4+/- 1.4 mm OBI, p = 0.07), or three dimensional (3.5+/-4.2 mm CBCT vs 3.6+/- 1.9 mm OBI, p = 0.52) vector averages. There was a statistical difference in the lateral vector (1.4+/-1.6 mm CBCT vs 1.7+/- 1.5 mm OBI, p < 0.001) of small magnitude. We found no clinically meaningful difference between the two imaging modalities for evaluating translational setup uncertainty.
Setup Uncertainty First Three Treatment Days vs. Subsequent Treatments via CBCT Image Guidance
Immobilization Device and Setup Uncertainty
Medications and Setup Uncertainty
Tumor Location and Setup Uncertainty
Effect of Custom PTV on Dose to OAR
The treatment of intracranial malignancies has been greatly enhanced by the use of radiation [8, 9]. The ultimate objective is to administer a dose localized at the target volume coupled with the desired effect of sparing normal tissue, thus, minimizing the likelihood of long-term neurocognitive deficits. Reducing the clinical target volume has been shown to be adequate for tumor control with the intention of diminishing the potential cognitive side effects inherent with radiation therapy . The use of three-dimensional conformal radiation therapy has been effective in increasing tumor control and in reducing acute side effects .
The determination of the setup uncertainty prior to the initiation of radiation plays an important role in the treatment of CNS malignancies. Daily setup variation may be underrecognized and may have an adverse impact, including target underdose and normal structures receiving a higher dose than anticipated [12, 13]. Daily localization based on cone beam CT imaging may reduce the required setup margin lessening normal tissue exposure to radiation . Patient motion during treatment may affect the dose to critical structures and, therefore, establishing risk volumes are recommended to accurately ascertain the dose administered to normal tissues .
Closely monitoring the target volume is vital during radiation therapy to ensure that the doses to the target and normal tissues are not altered which may have deleterious repercussions . Beltran et al. have demonstrated that the target volume during radiation therapy in craniopharyngioma may increase and decrease (-20.7% to 82%), stressing that surveillance imaging is necessary to determine the appropriate dose to the target volume while at the same time closely observing the amount to the normal tissue . Beltran et al. have also recommended daily localization which decreases the PTV margin and minimizes insufficient tumor coverage due to setup uncertainties . In addition, a decrease in the CTV margin lessens the dose directed to normal cerebral tissues .
Several studies have addressed daily setup variability in the treatment of head and neck cancer patients using conventional mask immobilization. Hong et al. showed a 3.33 mm absolute average daily setup error in any single dimension while other studies have reported a range of 3–5 mm in head and neck setup variation using weekly portal film measurements [12, 16, 17]. The patients in the current study were either immobilized with an aquaplast mask and either a base plate or S-frame. In our study, immobilization with an S-frame significantly increased setup uncertainty (3D p < 0.001) primarily in the vertical direction, consistent with flexion of the insert as it protrudes beyond the head of the table. Beltran et al. reported that the setup margin was smaller for those patients who were treated under anesthesia . In the present study, setup uncertainty was statistically significant in patients who received sedatives (3D p < 0.001). We hypothesize that patients at risk for claustrophobia requiring oral sedation in fact would have demonstrated larger variation without sedation, and in our study the sedation was unable to completely ameliorate their anxiety. Patients prescribed either steroids or anti-seizure medications demonstrated no statistical difference in setup uncertainty.
We have shown that there was no statistical difference in setup uncertainty between CBCT and OBI imaging modalities. In addition, setup uncertainty was not significant for the first three days of treatment versus all subsequent treatment days via CBCT guidance. The first three days of CBCT predicted setup uncertainty for subsequent treatments and permitted customized CTV to PTV expansion. Patient weight gain of greater than ten pounds was not associated with increased setup uncertainty. The data demonstrated that patients with a tumor located in the temporal lobe experienced greater setup uncertainty whereas those with pituitary tumors showed the least setup uncertainty.
Setup uncertainty in the course of radiation treatment may be influenced by several factors, including the immobilization device utilized in therapy, specific medications, and certain tumor locale. To minimize the setup uncertainty, various institutions have instituted a policy of daily and continuous evaluation of interfraction and intrafraction motion for all head and neck cancer patients undergoing intensity-modulated radiation therapy [12, 18].
Image-guidance potentially maximizes the therapeutic index of brain irradiation by minimizing setup uncertainty. Custom CTV to PTV expansion results in a reduced dose administered to the OAR which diminishes the possibility of developing neurocognitive, learning, and neuroendocrine deficits.
We acknowledge Norton Healthcare for their ongoing support.
- International Commission on Radiation Units and Measurements: ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU; 1993.Google Scholar
- Beltran C, Naik M, Merchant TE: Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma. Radiother Oncol 2010,96(2):216-222. 10.1016/j.radonc.2010.02.031View ArticlePubMedGoogle Scholar
- Beltran C, Trussell J, Merchant TE: Dosimetric impact of intrafractional patient motion in pediatric brain tumor patients. Med Dosim 2010,35(1):43-48. 10.1016/j.meddos.2009.01.004View ArticlePubMedPubMed CentralGoogle Scholar
- Beltran C, Krasin MJ, Merchant TE: Inter- and intrafractional positional uncertainties in pediatric radiotherapy patients with brain and head and neck tumors. Int J Radiat Oncol Biol Phys 2011,79(4):1266-1274. 10.1016/j.ijrobp.2009.12.057View ArticlePubMedPubMed CentralGoogle Scholar
- Cho BC, Cho BC, van Herk M, Mijnheer BJ, Bartelink H: The effect of set-up uncertainties, contour changes, and tissue inhomogeneities on target dose-volume histograms. Med Phys 2002,29(10):2305-2318. 10.1118/1.1508800View ArticlePubMedGoogle Scholar
- Rahimian J, Chen JC, Rao AA, Girvigian MR, Miller MJ, Greathouse HE: Geometrical accuracy of the Novalis stereotactic radiosurgery system for trigeminal neuralgia. J Neurosurg 2004,101(Suppl 3):351-355.PubMedGoogle Scholar
- O'Gorman RL, Jarosz JM, Samuel M, Clough C, Selway RP, Ashkan K: CT/MR image fusion in the postoperative assessment of electrodes implanted for deep brain stimulation. Stereotact Funct Neurosurg 2009,87(4):205-210. 10.1159/000225973View ArticlePubMedGoogle Scholar
- Merchant TE, Kun LE, Wu S, Xiong X, Sanford RA, Boop FA: Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol 2009,27(22):3598-3604. 10.1200/JCO.2008.20.9494View ArticlePubMedPubMed CentralGoogle Scholar
- Dunbar SF, Tarbell NJ, Kooy HM, Alexander E III, Black PM, Barnes PD, Goumnerova L, Scott RM, Pomeroy SL, La VB: Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol Biol Phys 1994,30(3):531-539. 10.1016/0360-3016(92)90938-EView ArticlePubMedGoogle Scholar
- Merchant TE, Kiehna EN, Kun LE, Mulhern RK, Li C, Xiong X, Boop FA, Sanford RA: Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function. J Neurosurg 2006,104(2 Suppl):94-102.PubMedGoogle Scholar
- Merchant TE: Three-dimensional conformal radiation therapy for ependymoma. Childs Nerv Syst 2009,25(10):1261-1268. 10.1007/s00381-009-0892-9View ArticlePubMedGoogle Scholar
- Hong TS, Tome WA, Chappell RJ, Chinnaiyan P, Mehta MP, Harari PM: The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005,61(3):779-788. 10.1016/j.ijrobp.2004.07.696View ArticlePubMedGoogle Scholar
- Kumar S, Burke K, Nalder C, Jarrett P, Mubata C, A'hern R, Humphreys M, Bidmead M, Brada M: Treatment accuracy of fractionated stereotactic radiotherapy. Radiother Oncol 2005,74(1):53-59. 10.1016/j.radonc.2004.06.008View ArticlePubMedGoogle Scholar
- Beltran C, Pai Panandiker AS, Krasin MJ, Merchant TE: Daily image-guided localization for neuroblastoma. J Appl Clin Med Phys 2010,11(4):3388.PubMedGoogle Scholar
- Beltran C, Naik M, Merchant TE: Dosimetric effect of target expansion and setup uncertainty during radiation therapy in pediatric craniopharyngioma. Radiother Oncol 2010,97(3):399-403. 10.1016/j.radonc.2010.10.017View ArticlePubMedGoogle Scholar
- Menke M, Hirschfeld F, Mack T, Pastyr O, Sturm V, Schlegel W: Photogrammetric accuracy measurements of head holder systems used for fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1994,29(5):1147-1155. 10.1016/0360-3016(94)90412-XView ArticlePubMedGoogle Scholar
- Rabinowitz I, Broomberg J, Goitein M, McCarthy K, Leong J: Accuracy of radiation field alignment in clinical practice. Int J Radiat Oncol Biol Phys 1985,11(10):1857-1867. 10.1016/0360-3016(85)90046-XView ArticlePubMedGoogle Scholar
- Tome WA, Meeks SL, McNutt TR, Buatti JM, Bova FJ, Friedman WA, Mehta M: Optically guided intensity modulated radiotherapy. Radiother Oncol 2001,61(1):33-44. 10.1016/S0167-8140(01)00414-5View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.